![Pharmacokinetics and Pharmacodynamics of DPC 333 ((2R)-2-((3R)-3-Amino-3{4-[2-methyl-4-quinolinyl) methoxy] phenyl}-2-oxopyrrolidinyl)-N-hydroxy-4-methylpentanamide)), a Potent and Selective Inhibitor of Tumor Necrosis Factor α-Converting Enzyme in ... Pharmacokinetics and Pharmacodynamics of DPC 333 ((2R)-2-((3R)-3-Amino-3{4-[2-methyl-4-quinolinyl) methoxy] phenyl}-2-oxopyrrolidinyl)-N-hydroxy-4-methylpentanamide)), a Potent and Selective Inhibitor of Tumor Necrosis Factor α-Converting Enzyme in ...](https://dmd.aspetjournals.org/content/dmd/35/10/1916/F1.large.jpg)
Pharmacokinetics and Pharmacodynamics of DPC 333 ((2R)-2-((3R)-3-Amino-3{4-[2-methyl-4-quinolinyl) methoxy] phenyl}-2-oxopyrrolidinyl)-N-hydroxy-4-methylpentanamide)), a Potent and Selective Inhibitor of Tumor Necrosis Factor α-Converting Enzyme in ...
![Novartis targets Johnson & Johnson's Remicade, Amgen's Enbrel with biosimilar switching data | Fierce Pharma Novartis targets Johnson & Johnson's Remicade, Amgen's Enbrel with biosimilar switching data | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1529050093/Industria_Novartis_wiki_andrew_flickr.jpg/Industria_Novartis_wiki_andrew_flickr.jpg?VersionId=IoTnEVXzhLHdKUJTNaBANsHxMbCcQqD9)
Novartis targets Johnson & Johnson's Remicade, Amgen's Enbrel with biosimilar switching data | Fierce Pharma
![Johnson & Johnson would be just fine without Zytiga, executives insist as patent decision looms | Fierce Pharma Johnson & Johnson would be just fine without Zytiga, executives insist as patent decision looms | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1539701594/JNJIOffice3.jpg/JNJIOffice3.jpg?VersionId=JzVW_2G89jDqlsllhjL7UVM56iXCpEoL)
Johnson & Johnson would be just fine without Zytiga, executives insist as patent decision looms | Fierce Pharma
![RCSB PDB - 2AIV: Multiple conformations in the ligand-binding site of the yeast nuclear pore targeting domain of NUP116P RCSB PDB - 2AIV: Multiple conformations in the ligand-binding site of the yeast nuclear pore targeting domain of NUP116P](https://cdn.rcsb.org/images/structures/2aiv_chain-A.jpeg)